Health-Economic Impact Attributable to Occurrence of Pleurisy and Pneumonia Lesions in Finishing Pigs.

Respiratory diseases, such as pleurisy and pneumonia, cause significant health and economic losses in pig production. This study evaluated 867 finishing pigs from a farm with a history of respiratory issues, using macroscopic lesion scoring (SPES and CVPC), histopathological analysis, qPCR diagnostics, and economic modeling. Severe pleurisy (scores 3 and 4) was observed in 42.

Shedding reduction and immunity modulation in piglets with an inactivated Mycoplasma hyopneumoniae vaccine encapsulated in nanostructured SBA-15 silica.

Mycoplasma (M.) hyopneumoniae is a primary etiological agent of porcine enzootic pneumonia (PEP), a disease that causes significant economic losses to pig farming worldwide. Current commercial M.

Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control in Swine Production.

is a difficult-to-control bacterium since commercial vaccines do not prevent colonization and excretion. The present study aimed to evaluate the performance of an orally administered vaccine composed of antigens extracted from and incorporated into mesoporous silica (SBA-15), which has an adjuvant-carrier function, aiming to potentiate the action of the commercial intramuscular vaccine. A total of 60 piglets were divided into four groups (n = 15) submitted to different vaccination protocols as follows, Group 1: oral SBA15 + commercial vaccine at 24 days after weaning, G2: oral vaccine on the third day of life + vaccine commercial vaccine at 24 days, G3: commercial vaccine at 24 days, and G4: commercial vaccine + oral vaccine at 24 days.